Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial

Abstract

Glargine treatment was well accepted and tolerated. No real efficacy in improving clinical and glycometabolic conditions was demonstrated. Further studies are necessary to test glargine at higher dosage and for a longer follow-up period.

Insulin therapy in patients with cystic fibrosis in the pre-diabetes stage: a systematic review

“…Three studies used control groups to compare the effects of insulin. Moran et al15 selected corresponding controls who underwent other types of intervention (repaglinide or placebo), while Minicucci et al16 used controls with IGT and Koloušková et al17 used controls with normal OGTT by ADA criteria (NGT). In these last two studies, controls did not undergo pharmacological interventions.…”

“…Koloušková et al17 and Drummond et al12 assessed FEV1 compared to untreated subjects and identified a decline in lung function in control group, which was not seen in insulin-treated group. Moran et al15 and Minicucci et al16 found no improvement in FEV1 with early use of insulin. However, in the study by Minicucci et al16 there was a 10% decrease in FEV1 in the year prior to the intervention, which may be a bias because even CFRD patients have no such decline in this parameter.…”

“…Moran et al15 and Minicucci et al16 found no improvement in FEV1 with early use of insulin. However, in the study by Minicucci et al16 there was a 10% decrease in FEV1 in the year prior to the intervention, which may be a bias because even CFRD patients have no such decline in this parameter. Koloušková et al17 and Drummond et al12 , who had a more consistent number of cases, found that FEV1 was lower in the untreated group compared to those treated with insulin, which confirms the results described by Dobson et al6 Bizarri et al20 , and Hameed et al19 …”

Insulinoterapia em pacientes com fibrose cística na fase de pré‐diabetes: uma revisão sistemática

“…Three studies used control groups to compare the effects of insulin. Moran et al15 selected corresponding controls who underwent other types of intervention (repaglinide or placebo), while Minicucci et al16 used controls with IGT and Koloušková et al17 used controls with normal OGTT by ADA criteria (NGT). In these last two studies, controls did not undergo pharmacological interventions.…”

“…Mozzillo et al18 used the following inclusion criteria: no use of systemic corticosteroids and no exacerbation of lung disease. Minicucci et al16 included patients with at least one of the following conditions: (I) body mass index BMI<10th percentile (p 10 ); (II) loss of one BMI percentile for age and sex in the previous year; (III) forced expiratory volume in one second (FEV1) ≤80% of predicted; and (IV) decreased FEV1≥10% in the previous year. Lung function deterioration and weight loss were also criteria for inclusion of subjects in the study by Dobson et al6 In contrast, Moran et al15 chose to intervene in a more clinically stable group of patients and used the following inclusion criteria: (I) end of linear growth; (II) weight stability in the last three months; (III) absence of acute infection in the last two months.…”